ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

GHENT, Belgium, 14 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] announces that it will present additional data from the two Phase IIb studies...